Advanced

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease : A prospective 9-year study

Stomrud, Erik LU ; Minthon, Lennart LU ; Zetterberg, Henrik LU ; Blennow, Kaj LU and Hansson, Oskar LU (2015) In Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 1(4). p.11-403
Abstract

INTRODUCTION: Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials.

METHODS: In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year period.

RESULTS: Low CSF β-amyloid (Aβ)42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one-third of individuals with pathologically low baseline Aβ42 levels remained cognitively intact during follow-up. No further decrease in Aβ42 was seen in those with low... (More)

INTRODUCTION: Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials.

METHODS: In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year period.

RESULTS: Low CSF β-amyloid (Aβ)42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one-third of individuals with pathologically low baseline Aβ42 levels remained cognitively intact during follow-up. No further decrease in Aβ42 was seen in those with low levels already at baseline.

DISCUSSION: CSF Aβ42 predicts sporadic AD at least 9 years before dementia onset and has plateaued already at this time. However, many individuals can harbor brain amyloid accumulation over a decade without signs of cognitive deterioration, which could implicate how CSF biomarkers are used to identify preclinical AD in future interventional therapeutic trials.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
volume
1
issue
4
pages
11 - 403
publisher
Elsevier
external identifiers
  • scopus:84946087516
ISSN
2352-8729
DOI
10.1016/j.dadm.2015.09.002
language
English
LU publication?
yes
id
913ec2b1-35c6-484f-81e8-ef5900bcd55c
date added to LUP
2019-05-31 13:12:31
date last changed
2019-09-17 04:55:46
@article{913ec2b1-35c6-484f-81e8-ef5900bcd55c,
  abstract     = {<p>INTRODUCTION: Ascertainment of the pattern and temporal change of biomarkers in preclinical (asymptomatic) sporadic Alzheimer's disease (AD) will increase knowledge about early pathogenesis and facilitate interventional therapeutic trials.</p><p>METHODS: In this prospective longitudinal study, repeated cerebrospinal fluid (CSF) collections and cognitive evaluations were performed in cognitively healthy elderly individuals during a 9-year period.</p><p>RESULTS: Low CSF β-amyloid (Aβ)42 levels predicted subsequent development of clinical AD 9 years later. Noteworthy, one-third of individuals with pathologically low baseline Aβ42 levels remained cognitively intact during follow-up. No further decrease in Aβ42 was seen in those with low levels already at baseline.</p><p>DISCUSSION: CSF Aβ42 predicts sporadic AD at least 9 years before dementia onset and has plateaued already at this time. However, many individuals can harbor brain amyloid accumulation over a decade without signs of cognitive deterioration, which could implicate how CSF biomarkers are used to identify preclinical AD in future interventional therapeutic trials.</p>},
  author       = {Stomrud, Erik and Minthon, Lennart and Zetterberg, Henrik and Blennow, Kaj and Hansson, Oskar},
  issn         = {2352-8729},
  language     = {eng},
  number       = {4},
  pages        = {11--403},
  publisher    = {Elsevier},
  series       = {Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring},
  title        = {Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease : A prospective 9-year study},
  url          = {http://dx.doi.org/10.1016/j.dadm.2015.09.002},
  volume       = {1},
  year         = {2015},
}